Slide background

> Our Technology

DCVax® is a platform
technology that uses
activated dendritic cells

Slide background

> Our Products

DCVax® – L
DCVax® – Direct
DCVax® – Prostate

Slide background

Northwest Biotherapeutics, Inc is a clinical stage biotechnology company focused on the development of personalized cancer vaccines designed to treat a broad range of solid tumor cancers.

Corporate Presentation

CEO Linda Powers

Northwest Bio's CEO presents at SMi's 3rd Cancer Vaccine Conference, detailing progress to-date, as well as the exciting announcement that DCVax-L received the first-ever "Promising Innovative Medicine" (PIM) designation under the UK's "Early Access to Medicines Scheme" (EAMS).

Shorts vs. NW Bio: Why Main Street Hates Wall Street


The Washington Post, Front Page Business Section, September 28, 2014
CLICK HERE TO READ THE FULL ARTICLE >>